Development Pipeline
Pancreatic first, with multi-cancer potential developed indication by indication.
PDAClocate™ is Genoll’s pancreatic-first diagnostic program. The pipeline is designed to progress from focused pancreatic cancer signal development into future cancer indications, with each indication requiring its own data, model, and clinical pathway.
Lead Program
PDAClocate™ begins with pancreatic cancer.
Genoll starts with pancreatic cancer because the early-detection gap is urgent and late-stage outcomes remain poor. PDAClocate™ is designed around blood-based molecular signal analysis, multi-omics evaluation, and clinician-reviewable reporting.
METHODOLOGY
Blood-Based Signal Analysis
We read genomic signals in venous blood, tuned for clear molecular detection.
INTEGRATION
Multi-Omics Evaluation
Combining multiple molecular data layers to improve signal-to-noise ratios and biological interpretation.
Staged Roadmap
A staged path to early diagnostic capabilities.
Planned Validation Benchmarks
- Plan signal-parameter review against South Asian cohort context.
- Prepare low-abundance circulating transcript signature review.
Evidence Base
Read the evidence backing our pipeline.
Explore our research program, cohort design methodologies, and focus on population-specific South Asian genetic signals.